Cantor Fitzgerald Issues Positive Outlook for SLDB Earnings

Solid Biosciences Inc. (NASDAQ:SLDB) – Stock analysts at Cantor Fitzgerald upped their FY2025 earnings per share (EPS) estimates for Solid Biosciences in a report issued on Wednesday, August 13th. Cantor Fitzgerald analyst K. Kluska now expects that the company will earn ($1.86) per share for the year, up from their previous forecast of ($2.06). Cantor Fitzgerald currently has a “Overweight” rating and a $16.00 target price on the stock. The consensus estimate for Solid Biosciences’ current full-year earnings is ($2.84) per share. Cantor Fitzgerald also issued estimates for Solid Biosciences’ FY2026 earnings at ($1.93) EPS.

A number of other brokerages also recently commented on SLDB. HC Wainwright reissued a “buy” rating and issued a $20.00 price target on shares of Solid Biosciences in a report on Tuesday, June 17th. Piper Sandler reduced their price target on Solid Biosciences from $20.00 to $17.00 and set an “overweight” rating for the company in a report on Friday, May 16th. Chardan Capital reissued a “buy” rating and issued a $15.00 price target on shares of Solid Biosciences in a report on Thursday. Barclays reduced their target price on Solid Biosciences from $15.00 to $10.00 and set an “overweight” rating on the stock in a report on Friday, May 16th. Finally, JMP Securities reaffirmed a “market outperform” rating and set a $15.00 target price on shares of Solid Biosciences in a report on Friday, June 6th. One analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $15.00.

Solid Biosciences Price Performance

Shares of NASDAQ SLDB opened at $6.11 on Friday. Solid Biosciences has a 1-year low of $2.41 and a 1-year high of $10.37. The business has a 50-day moving average of $5.62 and a 200-day moving average of $4.44. The company has a market capitalization of $475.79 million, a price-to-earnings ratio of -2.18 and a beta of 2.44.

Solid Biosciences (NASDAQ:SLDB) last issued its earnings results on Tuesday, August 12th. The company reported ($0.42) earnings per share for the quarter, topping the consensus estimate of ($0.51) by $0.09.

Institutional Trading of Solid Biosciences

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Bain Capital Life Sciences Investors LLC raised its stake in Solid Biosciences by 96.1% during the 1st quarter. Bain Capital Life Sciences Investors LLC now owns 7,911,669 shares of the company’s stock valued at $29,273,000 after acquiring an additional 3,877,087 shares in the last quarter. Siren L.L.C. raised its stake in Solid Biosciences by 97.8% during the 1st quarter. Siren L.L.C. now owns 7,415,905 shares of the company’s stock valued at $27,439,000 after acquiring an additional 3,666,864 shares in the last quarter. Adage Capital Partners GP L.L.C. raised its stake in Solid Biosciences by 285.0% during the 1st quarter. Adage Capital Partners GP L.L.C. now owns 6,729,484 shares of the company’s stock valued at $24,899,000 after acquiring an additional 4,981,400 shares in the last quarter. Vestal Point Capital LP raised its stake in Solid Biosciences by 1.8% during the 4th quarter. Vestal Point Capital LP now owns 2,850,000 shares of the company’s stock valued at $11,400,000 after acquiring an additional 50,000 shares in the last quarter. Finally, Redmile Group LLC raised its stake in Solid Biosciences by 228.2% during the 1st quarter. Redmile Group LLC now owns 2,019,171 shares of the company’s stock valued at $7,471,000 after acquiring an additional 1,403,925 shares in the last quarter. 81.46% of the stock is currently owned by institutional investors and hedge funds.

Solid Biosciences Company Profile

Solid Biosciences Inc, a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia.